pyrazinamide has been researched along with Co-infection in 27 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)." | 7.88 | [DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018) |
| " One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 5.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "Pyrazinamide is a first-line drug used in the treatment of tuberculosis." | 4.02 | Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing. ( Äbelö, A; Ashton, M; Bienvenu, E; Hoffmann, KJ; Sundell, J; Wijk, M, 2021) |
| "We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)." | 3.88 | [DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| " Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)." | 2.82 | Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| " Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
| "If isoniazid Cmax was <4." | 1.46 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
| " One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 1.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (92.59) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, H | 1 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Alshaer, MH | 1 |
| Peloquin, CA | 1 |
| Kwara, A | 1 |
| Sundell, J | 1 |
| Wijk, M | 1 |
| Bienvenu, E | 1 |
| Äbelö, A | 1 |
| Hoffmann, KJ | 1 |
| Ashton, M | 1 |
| Chirehwa, MT | 1 |
| McIlleron, H | 5 |
| Rustomjee, R | 2 |
| Mthiyane, T | 1 |
| Onyebujoh, P | 1 |
| Smith, P | 2 |
| Denti, P | 3 |
| Sekaggya-Wiltshire, C | 1 |
| Castelnuovo, B | 1 |
| von Braun, A | 1 |
| Musaazi, J | 1 |
| Muller, D | 1 |
| Buzibye, A | 1 |
| Gutteck, U | 1 |
| Henning, L | 1 |
| Ledergerber, B | 1 |
| Corti, N | 1 |
| Lamorde, M | 1 |
| Fehr, J | 1 |
| Kambugu, A | 1 |
| Wondale, B | 1 |
| Medihn, G | 1 |
| Teklu, T | 1 |
| Mersha, W | 1 |
| Tamirat, M | 1 |
| Ameni, G | 1 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 1 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Bhavani, PK | 1 |
| Gangadevi, NP | 1 |
| Swaminathan, S | 1 |
| Gupta, A | 1 |
| Dooley, KE | 1 |
| Savic, RM | 1 |
| Kombila, UD | 1 |
| Ka, W | 1 |
| Mbaye, FBR | 1 |
| Diouf, NF | 1 |
| Fall, L | 1 |
| Ouedraogo, P | 1 |
| Koutonin, ANE | 1 |
| Dia Kane, Y | 1 |
| Oumar Toure Badiane, N | 1 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| Zhao, Y | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Boulle, A | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Meintjes, G | 3 |
| Wasserman, S | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Pape, JW | 1 |
| Koenig, SP | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Kvasnovsky, C | 1 |
| Werner, L | 1 |
| Master, I | 1 |
| Horsburgh, CR | 1 |
| Smythe, W | 1 |
| Merle, CS | 1 |
| Gninafon, M | 1 |
| Lo, MB | 1 |
| Bah-Sow, O | 1 |
| Olliaro, PL | 1 |
| Lienhardt, C | 1 |
| Horton, J | 1 |
| Simonsson, US | 1 |
| Wejse, C | 1 |
| Furtado, A | 1 |
| Camara, C | 1 |
| Lüneborg-Nielsen, M | 1 |
| Sodemann, M | 1 |
| Gerstoft, J | 1 |
| Katzenstein, TL | 1 |
| Jindani, A | 1 |
| Harrison, TS | 1 |
| Nunn, AJ | 1 |
| Phillips, PP | 1 |
| Churchyard, GJ | 1 |
| Charalambous, S | 1 |
| Hatherill, M | 1 |
| Geldenhuys, H | 1 |
| McIlleron, HM | 2 |
| Zvada, SP | 1 |
| Mungofa, S | 1 |
| Shah, NA | 1 |
| Zizhou, S | 1 |
| Magweta, L | 1 |
| Shepherd, J | 1 |
| Nyirenda, S | 1 |
| van Dijk, JH | 1 |
| Clouting, HE | 1 |
| Coleman, D | 1 |
| Bateson, AL | 1 |
| McHugh, TD | 2 |
| Butcher, PD | 1 |
| Mitchison, DA | 1 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Ukwaja, KN | 1 |
| Oshi, DC | 1 |
| Martinez-Longoria, CA | 1 |
| Rubio-Perez, NE | 1 |
| Rios-Solis, JE | 1 |
| Garcia-Rodriguez, F | 1 |
| Honeyborne, I | 1 |
| Lipman, MC | 1 |
| Eckold, C | 1 |
| Evangelopoulos, D | 1 |
| Gillespie, SH | 1 |
| Pym, A | 2 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 1 |
| Jones-López, EC | 1 |
| Hennig, S | 1 |
| Naiker, S | 1 |
| Reddy, T | 1 |
| Egan, D | 1 |
| Kellerman, T | 1 |
| Wiesner, L | 3 |
| Owen, A | 1 |
| Bekker, A | 1 |
| Schaaf, HS | 2 |
| Draper, HR | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| Donald, PR | 2 |
| Hesseling, AC | 2 |
| Mukherjee, A | 1 |
| Velpandian, T | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Kabra, SK | 1 |
| Lodha, R | 1 |
| Rockwood, N | 2 |
| Chirehwa, M | 1 |
| Wilkinson, RJ | 2 |
| Sogebi, OA | 1 |
| Adefuye, BO | 1 |
| Adebola, SO | 1 |
| Oladeji, SM | 1 |
| Adedeji, TO | 1 |
| Pasipanodya, JG | 1 |
| Sirgel, F | 1 |
| Lesosky, M | 1 |
| Gumbo, T | 1 |
| Thee, S | 1 |
| Seddon, JA | 1 |
| Seifart, HI | 1 |
| Werely, CJ | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Magdorf, K | 1 |
| Trindade, MÂ | 1 |
| Miyamoto, D | 1 |
| Benard, G | 1 |
| Sakai-Valente, NY | 1 |
| Vasconcelos, Dde M | 1 |
| Naafs, B | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
| Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
| Arm A | 217 | 5 | 13 | 1 | 1 |
| Arm B | 121 | 1 | 9 | 1 | 0 |
| Arm C | 117 | 9 | 6 | 3 | 4 |
1 review available for pyrazinamide and Co-infection
| Article | Year |
|---|---|
Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.
Topics: Adult; Brazil; Coinfection; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-12; Is | 2013 |
6 trials available for pyrazinamide and Co-infection
| Article | Year |
|---|---|
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr | 2013 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C | 2014 |
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal | 2016 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
20 other studies available for pyrazinamide and Co-infection
| Article | Year |
|---|---|
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing.
Topics: Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Male; Pyrazinamide; Tuberculosis | 2021 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh | 2017 |
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema | 2017 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
[DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment].
Topics: Adrenal Cortex Hormones; Adult; Antitubercular Agents; Coinfection; Drug Hypersensitivity Syndrome; | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Etham | 2013 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Severe meningoencephalitis co-infection due to Cryptococcus neoformans and Mycobacterium tuberculosis in a child with systemic lupus erythematosus.
Topics: Amphotericin B; Antitubercular Agents; Child; Coinfection; Cryptococcosis; Cryptococcus neoformans; | 2015 |
Effective anti-tuberculosis therapy correlates with plasma small RNA.
Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur | 2016 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; | 2017 |
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV | 2017 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |